Profile data is unavailable for this security.
About the company
Virpax Pharmaceuticals, Inc. is a preclinical-stage pharmaceutical company. The Company is focused on developing novel and proprietary drug delivery systems across various pain indication. Its drug-delivery systems and drug-releasing technologies being developed are focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system (CNS) disorders to enhance patients’ quality of life. Its portfolio consists of multiple preclinical stage product candidates: Epoladerm, Probudur, Envelta, AnQlar and NobrXiol. Probudur is a single injection liposomal bupivacaine formulation being developed to manage post-operative pain. Envelta is an intranasal molecular envelope enkephalin formulation being developed to manage acute and chronic pain, including pain associated with cancer. The NobrXiol is being developed for the nasal delivery of a pharmaceutical-grade cannabidiol (CBD) for the management of rare pediatric epilepsy.
- Revenue in USD (TTM)0.00
- Net income in USD-17.23m
- Incorporated2018
- Employees7.00
- LocationVirpax Pharmaceuticals Inc1055 Westlakes Drive, Suite 300BERWYN 19312United StatesUSA
- Phone+1 (610) 727-4597
- Fax+1 (302) 636-5454
- Websitehttps://virpaxpharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Allarity Therapeutics Inc | 0.00 | -12.82m | 3.16m | 5.00 | -- | 0.1319 | -- | -- | -2,217.58 | -2,217.58 | 0.00 | 16.98 | 0.00 | -- | -- | 0.00 | -52.54 | -- | -110.73 | -- | -- | -- | -- | -- | -- | -- | 0.0626 | -- | -- | -- | 3.02 | -- | -- | -- |
| Talis Biomedical Corp | 408.00k | -51.03m | 3.19m | 99.00 | -- | 0.0656 | -- | 7.82 | -28.02 | -28.02 | 0.224 | 26.69 | 0.0042 | -- | 1.53 | 4,121.21 | -52.13 | -68.18 | -57.23 | -74.22 | 95.10 | -- | -12,506.37 | -1,615.96 | -- | -- | 0.00 | -- | -55.65 | -2.24 | 45.13 | -- | -1.83 | -- |
| Tharimmune Inc | 0.00 | -8.88m | 3.20m | 2.00 | -- | 0.4552 | -- | -- | -55.46 | -55.46 | 0.00 | 6.11 | 0.00 | -- | -- | 0.00 | -138.06 | -- | -181.81 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -9.98 | -- | -- | -- |
| CTT Pharmaceutical Holdings Inc | 0.00 | -1.67m | 3.22m | 0.00 | -- | 1.73 | -- | -- | -0.0822 | -0.0822 | 0.00 | 0.0346 | 0.00 | -- | -- | -- | -317.28 | 13.49 | -448.83 | 304.48 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -3,454.52 | -- | -- | -- |
| Lipella Pharmaceuticals Inc | 507.20k | -4.14m | 3.29m | 5.00 | -- | 1.83 | -- | 6.48 | -0.6188 | -0.6188 | 0.074 | 0.224 | 0.1788 | -- | 16.01 | 101,440.00 | -146.02 | -- | -169.27 | -- | -- | -- | -816.72 | -- | -- | -- | 0.00 | -- | 144.15 | -- | -77.81 | -- | -- | -- |
| InMed Pharmaceuticals Inc | 5.63m | -6.08m | 3.29m | 13.00 | -- | 0.133 | -- | 0.5848 | -1.23 | -1.23 | 0.9284 | 1.75 | 0.4006 | 2.71 | 29.77 | -- | -43.26 | -88.10 | -50.03 | -104.19 | 39.20 | -- | -108.01 | -1,066.11 | 5.80 | -- | 0.00 | -- | 279.60 | -- | 57.27 | -- | 29.56 | -- |
| Ensysce Biosciences Inc | 1.44m | -11.28m | 3.32m | 7.00 | -- | 1.33 | -- | 2.31 | -2.98 | -2.98 | 0.2845 | 0.2218 | 0.3142 | -- | 8.67 | 205,418.60 | -246.46 | -17.68 | -376.98 | -19.42 | -- | -- | -784.43 | -715.78 | -- | -5.93 | 0.235 | -- | -11.61 | -- | 57.64 | -- | -- | -- |
| Petros Pharmaceuticals Inc | 4.12m | -20.64m | 3.38m | 21.00 | -- | 0.4058 | -- | 0.8211 | -6.54 | -6.54 | 1.00 | 0.988 | 0.1529 | 0.6795 | 1.89 | 196,223.30 | -26.18 | -32.43 | -39.25 | -68.05 | 70.21 | 62.04 | -171.23 | -201.70 | 1.26 | -- | 0.4539 | -- | -2.83 | -16.15 | 31.06 | -- | -- | -- |
| Virpax Pharmaceuticals Inc | 0.00 | -17.23m | 3.41m | 7.00 | -- | -- | -- | -- | -13.51 | -13.51 | 0.00 | -0.9847 | 0.00 | -- | -- | 0.00 | -185.82 | -87.52 | -362.29 | -116.56 | -- | -- | -- | -- | -- | -1,596.37 | -- | -- | -- | -- | 29.84 | -- | -- | -- |
| Avenue Therapeutics Inc | 0.00 | -5.87m | 3.42m | 3.00 | -- | 0.5969 | -- | -- | -3.02 | -3.02 | 0.00 | 4.00 | 0.00 | -- | -- | 0.00 | -177.94 | -186.91 | -- | -287.70 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -192.15 | -- | -- | -- |
| Bone Biologics Corp | 0.00 | -5.12m | 3.49m | 2.00 | -- | 0.8773 | -- | -- | -10.26 | -10.26 | 0.00 | 2.21 | 0.00 | -- | -- | 0.00 | -94.66 | -98.31 | -119.03 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -502.76 | -- | -- | -- |
| Artelo Biosciences Inc | 0.00 | -10.44m | 3.52m | 5.00 | -- | 0.482 | -- | -- | -3.33 | -3.33 | 0.00 | 2.26 | 0.00 | -- | -- | 0.00 | -82.83 | -- | -88.23 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 7.87 | -- | -- | -- |
| Theriva Biologics Inc | 0.00 | -22.27m | 3.53m | 21.00 | -- | 2.96 | -- | -- | -1.25 | -1.25 | 0.00 | 1.23 | 0.00 | -- | -- | 0.00 | -41.30 | -36.95 | -48.49 | -40.16 | -- | -- | -- | -- | -- | -- | 0.0056 | -- | -- | -- | 8.37 | -- | 95.91 | -- |
| Halberd Corp | 281.24k | 25.34k | 3.62m | 3.00 | 2.46 | -- | 142.87 | 12.89 | 0.0023 | 0.0023 | 0.0018 | -0.0002 | 0.1449 | 0.0303 | 2.52 | -- | 1.31 | -- | 4.58 | -- | 50.00 | -- | 9.01 | -- | 0.2661 | 1.35 | 1.02 | -- | 271.52 | -- | -60.11 | -- | -- | -- |
| NovaBay Pharmaceuticals Inc | 12.02m | -15.98m | 3.65m | 24.00 | -- | -- | -- | 0.3036 | -65.73 | -65.91 | 21.94 | -0.4577 | 1.21 | 2.29 | 7.59 | 500,958.30 | -105.75 | -61.51 | -205.52 | -83.89 | 58.55 | 59.99 | -87.67 | -86.47 | 0.4302 | -- | 8.81 | -- | 2.24 | 3.32 | -2.66 | -- | -15.46 | -- |
Data as of Sep 24 2024. Currency figures normalised to Virpax Pharmaceuticals Inc's reporting currency: US Dollar USD
0.79%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Warberg Asset Management LLCas of 30 Jun 2024 | 20.00k | 0.73% |
| Tower Research Capital LLCas of 31 Mar 2024 | 1.45k | 0.05% |
| Signature Resources Capital Management LLCas of 30 Jun 2024 | 50.00 | 0.00% |
| Morgan Stanley Smith Barney LLC (Investment Management)as of 31 Mar 2024 | 15.00 | 0.00% |
| Hantz Financial Services, Inc.as of 30 Jun 2024 | 10.00 | 0.00% |
| Wells Fargo Bank, NA (Private Banking)as of 31 Mar 2024 | 8.00 | 0.00% |
| Parallel Advisors LLCas of 30 Jun 2024 | 1.00 | 0.00% |
| G1 Execution Services LLCas of 31 Mar 2024 | 0.00 | 0.00% |
| JPMorgan Securities LLC (Investment Management)as of 31 Mar 2024 | 0.00 | 0.00% |
| Osaic Wealth, Inc. (Investment Management)as of 31 Mar 2024 | 0.00 | 0.00% |
More ▼
Data from 31 Mar 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
